119 related articles for article (PubMed ID: 30161160)
1. A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study.
Onishi H; Udagawa C; Kubo M; Nakamura S; Akashi-Tanaka S; Kuwayama T; Watanabe C; Takamaru T; Takei H; Ishikawa T; Miyahara K; Matsumoto H; Hasegawa Y; Momozawa Y; Low SK; Kutomi G; Shima H; Satomi F; Okazaki M; Zaha H; Onomura M; Matsukata A; Sagara Y; Baba S; Yamada A; Shimada K; Shimizu D; Tsugawa K; Shimo A; Hartman M; Chan CW; Lee SC; Endo I; Zembutsu H
PLoS One; 2018; 13(8):e0201606. PubMed ID: 30161160
[TBL] [Abstract][Full Text] [Related]
2. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
Kiyotani K; Mushiroda T; Tsunoda T; Morizono T; Hosono N; Kubo M; Tanigawara Y; Imamura CK; Flockhart DA; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
Hum Mol Genet; 2012 Apr; 21(7):1665-72. PubMed ID: 22180457
[TBL] [Abstract][Full Text] [Related]
3. Significant Effect of Polymorphisms in
Zembutsu H; Nakamura S; Akashi-Tanaka S; Kuwayama T; Watanabe C; Takamaru T; Takei H; Ishikawa T; Miyahara K; Matsumoto H; Hasegawa Y; Kutomi G; Shima H; Satomi F; Okazaki M; Zaha H; Onomura M; Matsukata A; Sagara Y; Baba S; Yamada A; Shimada K; Shimizu D; Tsugawa K; Shimo A; Tan EY; Hartman M; Chan CW; Lee SC; Nakamura Y
Clin Cancer Res; 2017 Apr; 23(8):2019-2026. PubMed ID: 27797974
[No Abstract] [Full Text] [Related]
4. A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population.
Nakano MH; Udagawa C; Shimo A; Kojima Y; Yoshie R; Zaha H; Abe N; Motonari T; Unesoko M; Tamura K; Shimoi T; Yoshida M; Yoshida T; Sakamoto H; Kato K; Mushiroda T; Tsugawa K; Zembutsu H
Biol Pharm Bull; 2019 Dec; 42(12):2045-2053. PubMed ID: 31597885
[TBL] [Abstract][Full Text] [Related]
5. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
Breast Cancer; 2015 Jan; 22(1):71-8. PubMed ID: 23479208
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
9. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
10. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Dowsett M; Harper-Wynne C; Boeddinghaus I; Salter J; Hills M; Dixon M; Ebbs S; Gui G; Sacks N; Smith I
Cancer Res; 2001 Dec; 61(23):8452-8. PubMed ID: 11731427
[TBL] [Abstract][Full Text] [Related]
11. The effect of tamoxifen on expression of ER, PR, Cerb-B2, and ki-67 in C3H mice spontaneous breast cancer model and the relation with chemotherapeutic effect.
Li X; Zhang S; Liu W; Li H
Cell Biochem Biophys; 2014 Dec; 70(3):1875-9. PubMed ID: 25168102
[TBL] [Abstract][Full Text] [Related]
12. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
13. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
15. Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province.
Jiang Y; Han J; Liu J; Zhang G; Wang L; Liu F; Zhang X; Zhao Y; Pang D
Breast Cancer Res Treat; 2011 Jul; 128(1):251-7. PubMed ID: 21197568
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
17. Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma.
Morena AM; Oshima CT; Gebrim LH; Egami MI; Silva MR; Segreto RA; Giannotti Filho O; Teixeira VP; Segreto HR
Neoplasma; 2004; 51(6):481-6. PubMed ID: 15640959
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
Gago FE; Fanelli MA; Ciocca DR
J Steroid Biochem Mol Biol; 2006 Jan; 98(1):36-40. PubMed ID: 16188438
[TBL] [Abstract][Full Text] [Related]
19. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G;
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):951s-8s. PubMed ID: 15701892
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
